• Héctor Oviedo-Cruz, Erika R Carrasco-Blancas, and Marco A Cortes-Martínez.
• Department of Maternal-Fetal Medicine, Medical Center for Specialized Fetal Care, Hospital Español de México.
• Gac Med Mex. 2021 Jan 1; 157 (5): 537-546.

BackgroundNo preeclampsia screening test has been validated in our country.ObjectiveTo assess the fit and performance of the FMF 4.0 Bayesian algorithm in a Mexican population.MethodCohort study in singleton pregnancies, according to the competing risks model for preeclampsia. A priori risk was calculated based on medical history. Mean blood pressure (MBP), uterine artery mean pulsatility index (UtAmPI) and pregnancy-associated plasma protein A (PAPP-A) were measured at 11-14 weeks of gestation using standardized methodology. The value of each marker was transformed into multiples of the median (MoM) by the originala algorithm and by population-correctionb. Multivariate normal distribution and Bayes theorem were applied to obtain post-test probabilities.ResultsThere was 5.0% (40/807) of preeclampsia. Distributions in women without preeclampsia were MBP = 0.927a vs. 0.991b, UtAmPI = 0.895a vs. 1.030b and PAPP-A = 0.815a vs. 0.963b (p < 0.001). The AUC was 0.821a vs. 0.823b. For a detection rate of 69 %, cutoff points were 1 in 240a and 1 in 120b, with false positive rates of 31 %a and 29 %b.ConclusionsThe model has to be adjusted to the target population.Copyright: © 2021 Permanyer.

19 keywords...

hide…